Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sgx-523. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET known ✓ | P08581 | 20/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 9/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 9/20 | 1.00 |
| ▸ | NQO2 | P16083 | 2/20 | 1.00 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | MAPK8 | P45983 | 1/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 1/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 1/20 | 1.00 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 1.00 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.65 |
| ▸ | PDE2A | O00408 | 1/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.65 |
| ▸ | PDE4A | P27815 | 1/20 | 0.65 |
| ▸ | PDE1A | P54750 | 1/20 | 0.65 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.65 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.65 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sgx-523 SCHEMBL30222396 | 1.00 | MET (1.00) | METPDE3BPDE3ANQO2PIP4K2C | |
| Sgx-523 SCHEMBL4496422 | 1.00 | MET (1.00) | METPDE3BPDE3ANQO2PIP4K2C | |
| SCHEMBL4252065 | 0.87 | MET (0.77) | METPDE3BPDE3ANQO2PIP4K2C | |
| SCHEMBL4500316 | 0.87 | MET (0.76) | METPDE3BPDE3ANQO2PIP4K2C | |
| SCHEMBL4499219 | 0.86 | MET (0.76) | METPDE3BPDE3ANQO2PIP4K2C | |
| SCHEMBL15177005 | 0.86 | MET (0.76) | METPDE3BPDE3ANQO2PIP4K2C | |
| SCHEMBL509206 | 0.86 | MET (0.75) | METPDE3BPDE3ANQO2PIP4K2C | |
| SCHEMBL4497159 | 0.86 | MET (0.75) | METPDE3BPDE3ANQO2PIP4K2C | |
| SCHEMBL4255231 | 0.85 | MET (0.75) | METPDE3BPDE3ANQO2PIP4K2C | |
| SCHEMBL4255545 | 0.85 | MET (0.75) | METPDE3BPDE3ANQO2PIP4K2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 910 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522873-B2 | ALK and NTRK1 fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2026-01-13 | — | — | US | claimed |
| WO-2025216949-A1 | METHODS FOR TREATING A TUMOR WITH ANTI-CDH6 ANTIBODY DRUG CONJUGATES | ONCUSP THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | WO | claimed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| WO-2025122699-A1 | CDC7 INHIBITOR COMBINATIONAL THERAPY | Lin Bioscience, Inc. (TW) | 2025-06-12 | — | — | WO | claimed |
| US-12274699-B2 | Methods of treating cholangiocarcinoma | FOUNDATION MEDICINE, INC. (US) | 2025-04-15 | — | — | US | claimed |
| US-20250090495-A1 | CDC7 Inhibitor Combinational Therapy | Lin Bioscience, Inc. (TW) | 2025-03-20 | — | — | US | claimed |
| US-20240374571-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS | NOVARTIS AG (CH) | 2024-11-14 | — | — | US | claimed |
| EP-4395769-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS | Novartis AG (CH) | 2024-07-10 | — | — | EP | claimed |
| WO-2024102187-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | PINETREE THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | claimed |
| CN-117835978-A | Pharmaceutical combinations comprising TEAD inhibitors and their use for cancer treatment | 诺华股份有限公司 | 2024-04-05 | — | — | CN | claimed |
| WO-2024011307-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-SULFONAMIDE DERIVATIVES FOR THE INHIBITION OF SGK-1 AND TREATMENT OF CANCER | THRYV THERAPEUTICS INC. (CA) | 2024-01-18 | — | — | WO | claimed |
| US-20230372338-A1 | METHODS OF TREATING CHOLANGIOCARCINOMA | FOUNDATION MEDICINE, INC. (US) | 2023-11-23 | — | — | US | claimed |
| US-11771698-B2 | Methods of treating cholangiocarcinoma | FOUNDATION MEDICINE, INC. (US) | 2023-10-03 | — | — | US | claimed |
| WO-2023031781-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS | NOVARTIS AG (CH) | 2023-03-09 | — | — | WO | claimed |
| US-20220412957-A1 | METHODS OF TREATING CANCER PATIENTS WITH RAS NODE OR RTK TARGETED THERAPEUTIC AGENTS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2022-12-29 | — | — | US | claimed |
| EP-4073516-A1 | METHODS OF TREATING CANCER PATIENTS WITH RAS NODE OR RTK TARGETED THERAPEUTIC AGENTS | Celcuity Inc. (US) | 2022-10-19 | — | — | EP | claimed |
| EP-4048809-B1 | SYSTEMS AND METHODS FOR PREDICTING THERAPEUTIC SENSITIVITY | TEMPUS AI INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12637453-B2 | Pyrazolopyridine inhibitors of c-Jun-n-Terminal kinases and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| WO-2022019920-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | VERASTEM, INC. (US) | 2022-01-27 | — | — | WO | disclosed |
| US-11230589-B2 | Fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230589-B2 | Fusion molecules and uses thereof | RPS27A, CD2BP2, FGB | MET 714/4885PDE3B 4066/4885PDE3A 4268/4885 |
| US-20230372338-A1 | METHODS OF TREATING CHOLANGIOCARCINOMA | HCCS, PNLIP, LIPA | MET 444/4885PDE3B 1570/4885PDE3A 1675/4885 |
| US-20240374571-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS | TP53, TEAD2, SERPINB1 | MET 432/4885PDE3B 400/4885PDE3A 858/4885 |
| US-20250090495-A1 | CDC7 Inhibitor Combinational Therapy | CDC7, MCM7, BOD1L1 | MET 3735/4885PDE3B 1776/4885PDE3A 2442/4885 |
| US-12274699-B2 | Methods of treating cholangiocarcinoma | HCCS, PNLIP, LIPA | MET 444/4885PDE3B 1570/4885PDE3A 1675/4885 |
| US-12637453-B2 | Pyrazolopyridine inhibitors of c-Jun-n-Terminal kinases and uses thereof | MAP3K1, MAP3K3, MAPK1 | MET 1644/4885PDE3B 2620/4885PDE3A 1811/4885 |
| US-11771698-B2 | Methods of treating cholangiocarcinoma | HCCS, PNLIP, LIPA | MET 444/4885PDE3B 1570/4885PDE3A 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.